FAQ: APO-go® (apomorphine hydrochloride) therapies during the COVID-19 pandemic

FAQ for healthcare professionals: APO-go® (apomorphine hydrochloride) therapies during the COVID-19 pandemic.

Last reviewed
  • Treatments and medication
Resource type
  • Publications
  • All professions
  • Complex

This frequently asked questions document covers queries that healthcare professionals may receive from patients regarding APO-go® (apomorphine hydrochloride) products during the COVID-19 pandemic.

This document has been made available by Britannia Pharmaceuticals for use by healthcare professionals.

By clicking to to download the below document you are confirming that you are a healthcare professional.

Please note the FAQ is currently being revised and the updated version will be available soon.

More conferences for professionals

Explore a range of conferences and events for professionals